|
|
Volumn 20, Issue 3, 2015, Pages 241-242
|
|
Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
LAPATINIB;
ANTINEOPLASTIC AGENT;
QUINAZOLINE DERIVATIVE;
ARTICLE;
CLINICAL ARTICLE;
DIARRHEA;
DRUG ACTIVITY;
DRUG SAFETY;
FEBRILE NEUTROPENIA;
HUMAN;
HYPERTHERMIC THERAPY;
MAXIMUM TOLERATED DOSE;
NAUSEA AND VOMITING;
NEPHROTOXICITY;
NEUTROPENIA;
PRIORITY JOURNAL;
SKIN TOXICITY;
THROMBOCYTOPENIA;
UTERINE CERVIX CARCINOMA;
CARCINOMA;
CLINICAL TRIAL;
DOSE RESPONSE;
FEMALE;
MULTIMODALITY CANCER THERAPY;
PHASE 1 CLINICAL TRIAL;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
UTERINE CERVICAL NEOPLASMS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA;
CISPLATIN;
COMBINED MODALITY THERAPY;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
HUMANS;
HYPERTHERMIA, INDUCED;
NEOPLASM RECURRENCE, LOCAL;
QUINAZOLINES;
TREATMENT OUTCOME;
UTERINE CERVICAL NEOPLASMS;
|
|
EID: 84925453759
PISSN: 10837159
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2014-0365 Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|
